CellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Develops novel therapies to reduce the burden of neurodegenerative diseases
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases